Comparison Overview

Merck KGaA, Darmstadt, Germany

VS

AUROBINDO PHARMA LTD

Merck KGaA, Darmstadt, Germany

Frankfurter Str. 250, Darmstadt, DE, 64293
Last Update: 2025-12-09
Between 800 and 849

We are Merck KGaA, Darmstadt, Germany and its global affiliates. We are a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Privacy Statement: https://www.emdgroup.com/en/privacy-statement.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,264
Subsidiaries: 3
12-month incidents
0
Known data breaches
0
Attack type number
0

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, Telangana, IN, 500032
Last Update: 2025-12-09
Between 750 and 799

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,616
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/emd-affiliates-of-merck-kgaa-darmstadt-germany.jpeg
Merck KGaA, Darmstadt, Germany
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Merck KGaA, Darmstadt, Germany
100%
Compliance Rate
0/4 Standards Verified
AUROBINDO PHARMA LTD
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Merck KGaA, Darmstadt, Germany in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2025.

Incident History — Merck KGaA, Darmstadt, Germany (X = Date, Y = Severity)

Merck KGaA, Darmstadt, Germany cyber incidents detection timeline including parent company and subsidiaries

Incident History — AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/emd-affiliates-of-merck-kgaa-darmstadt-germany.jpeg
Merck KGaA, Darmstadt, Germany
Incidents

No Incident

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
Incidents

No Incident

FAQ

Merck KGaA, Darmstadt, Germany company demonstrates a stronger AI Cybersecurity Score compared to AUROBINDO PHARMA LTD company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, AUROBINDO PHARMA LTD company has disclosed a higher number of cyber incidents compared to Merck KGaA, Darmstadt, Germany company.

In the current year, AUROBINDO PHARMA LTD company and Merck KGaA, Darmstadt, Germany company have not reported any cyber incidents.

Neither AUROBINDO PHARMA LTD company nor Merck KGaA, Darmstadt, Germany company has reported experiencing a ransomware attack publicly.

Neither AUROBINDO PHARMA LTD company nor Merck KGaA, Darmstadt, Germany company has reported experiencing a data breach publicly.

Neither AUROBINDO PHARMA LTD company nor Merck KGaA, Darmstadt, Germany company has reported experiencing targeted cyberattacks publicly.

Neither Merck KGaA, Darmstadt, Germany company nor AUROBINDO PHARMA LTD company has reported experiencing or disclosing vulnerabilities publicly.

Neither Merck KGaA, Darmstadt, Germany nor AUROBINDO PHARMA LTD holds any compliance certifications.

Neither company holds any compliance certifications.

Merck KGaA, Darmstadt, Germany company has more subsidiaries worldwide compared to AUROBINDO PHARMA LTD company.

AUROBINDO PHARMA LTD company employs more people globally than Merck KGaA, Darmstadt, Germany company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Merck KGaA, Darmstadt, Germany nor AUROBINDO PHARMA LTD holds SOC 2 Type 1 certification.

Neither Merck KGaA, Darmstadt, Germany nor AUROBINDO PHARMA LTD holds SOC 2 Type 2 certification.

Neither Merck KGaA, Darmstadt, Germany nor AUROBINDO PHARMA LTD holds ISO 27001 certification.

Neither Merck KGaA, Darmstadt, Germany nor AUROBINDO PHARMA LTD holds PCI DSS certification.

Neither Merck KGaA, Darmstadt, Germany nor AUROBINDO PHARMA LTD holds HIPAA certification.

Neither Merck KGaA, Darmstadt, Germany nor AUROBINDO PHARMA LTD holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.

Risk Information
cvss3
Base: 9.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:H
Description

Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.

Risk Information
cvss3
Base: 8.2
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:N
Description

Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.

Risk Information
cvss3
Base: 8.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:H/A:L
Description

The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.

Risk Information
cvss3
Base: 5.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:R/S:U/C:H/I:L/A:N